Objective:

To investigate whether baseline erythrocyte lifespan (ELS) can predict the development of moderate to severe anemia in advanced gastric cancer (AGC) patients undergoing anti-tumor treatments, highlighting the clinical significance of such predictions.

Key Findings:

• ELS was positively correlated with hemoglobin, age, hematocrit, and mean corpuscular hemoglobin concentration (MCHC), indicating potential predictive factors for anemia.
• Patients with ELS < 70 days had significantly lower hemoglobin levels compared to those with ELS ≥ 70 days, suggesting a threshold for clinical concern.
• No significant difference in ELS was found between patients with moderate-to-severe anemia and those without anemia, indicating a need for further investigation.

Interpretation:

The study suggests that ELS may serve as a predictive marker for hemoglobin levels in AGC patients, indicating a potential for personalized management of anemia, which could improve treatment outcomes.

Limitations:

• The study was conducted at a single center, which may limit generalizability and introduce selection bias.
• The sample size of 56 patients may not be sufficient to draw definitive conclusions, necessitating larger studies.

Conclusion:

Baseline ELS could be a valuable predictor for anemia in AGC patients undergoing treatment, potentially guiding better management strategies, but further research is needed to validate these findings.